Omnicell, Inc. — Q3 2021 Form 10-Q
Reporting period: Three and nine months ended September 30, 2021; unaudited. Omnicell provides medication-management automation, pharmacy software, and related services to healthcare systems and pharmacies. It reports as one operating segment.
Financial performance
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | $296.4m | $213.7m | $821.0m | $643.0m |
| Gross profit / margin | $146.8m / 49.5% | $96.8m / 45.3% | $405.4m / 49.4% | $289.6m / 45.0% |
| Operating income / margin | $29.4m / 9.9% | $10.2m / 4.8% | $77.9m / 9.5% | $15.3m / 2.4% |
| Net income | $29.3m | $8.8m | $63.9m | $15.8m |
| Diluted EPS | $0.61 | $0.20 | $1.35 | $0.36 |
Q3 product revenue was $214.0m, up 41%; services and other revenue was $82.4m, up 32%. For the nine-month period, product revenue rose 28% and services and other revenue rose 27%. Connected devices, software licenses, and other were the largest revenue category. U.S. sales represented 92% of Q3 revenue and 90% of nine-month revenue.
Cash flow and liquidity: Nine-month operating cash flow was $172.2m, versus $109.4m a year earlier. Investing cash outflow was $220.1m, including $178.1m for the FDS Amplicare acquisition, $24.1m for external-use software development, and $17.9m for property and equipment. Financing cash inflow was $40.7m. Cash and cash equivalents were $481.5m at September 30, 2021, versus $485.9m at year-end 2020; working capital was $550.1m and the current ratio was 2.6:1.
Debt: Convertible senior notes had $575m principal and a $482.8m net carrying amount; the notes bear 0.25% coupon interest and mature in September 2025. No borrowings were outstanding under the $500m revolving facility, which expires in November 2024; the company reported covenant compliance. The notes became convertible at holders’ option in Q4 2021 after the share-price conversion condition was met. Their reported fair value was $917.0m, and the filing states the if-converted value exceeded principal by $302.0m.
Material changes and notable items
- Revenue growth reflected stronger customer demand, especially for automated dispensing systems, and comparison with pandemic-affected 2020 periods. Management cited higher volumes and economies of scale as contributors to improved gross margin.
- Operating expenses increased 35% in Q3, including higher employee costs, acquisition-related and commission expenses, and renewed travel and trade-show spending. Nine-month R&D expense declined 2%, while SG&A rose 25%.
- Interest and other expense increased, mainly from discount and issuance-cost amortization and interest on the 2020 convertible notes. The nine-month income-tax provision included a $21.4m net discrete tax benefit, primarily $14.5m related to equity compensation and a $6.2m release of uncertain tax benefits.
- FDS Amplicare was acquired September 9, 2021, for a preliminary purchase price of $178.5m. Preliminary allocation included $118.8m of goodwill and $69.6m of identifiable intangible assets; purchase-price adjustments remained subject to finalization. The company also included the 340B Link acquisition, completed in October 2020, in current-period results.
- Deferred revenue totaled $128.9m, up from $105.7m at December 31, 2020. Non-cancelable purchase commitments were $130.7m, including $88.8m expected to be paid during the remainder of 2021.
Outlook, risks, and contingencies
The filing gives no specific numerical revenue or earnings guidance. Management said the recovery in customer purchasing patterns that began in late 2020 continued through Q3 2021, while noting that the pandemic’s duration and effects remain uncertain. Management expected cash, operating cash flows, employee equity-plan proceeds, and available credit to fund needs for at least the next 12 months and anticipated funding ongoing growth beyond that period.
Key risks include COVID-19 effects on customers, employees, and suppliers; reported semiconductor-chip shortages, component delays, and rising commodity costs; the ability to complete installations and meet demand; and successful integration of acquisitions. The company also identified risks from subscription-model adoption and revenue timing, healthcare-sector budget and regulatory changes, and potential impairment of acquisition-related goodwill and intangibles.
Omnicell disclosed two principal legal matters: a putative Illinois biometric-privacy class action and a trade-secret lawsuit brought by Becton, Dickinson and Company. The company intends to defend both. It recorded no material legal accrual, stating potential losses were reasonably possible but not probable and that a range could not be reasonably estimated or was not considered material. Disclosure controls were reported effective; management reported no material change in internal control over financial reporting during the quarter.
Investor verification priorities
- Assess whether revenue growth and margin improvement are sustainable as customer demand, installation timing, and 2020 comparisons normalize.
- Monitor semiconductor and other supply constraints, procurement costs, and the company’s ability to deliver products on schedule.
- Review the final FDS Amplicare purchase-price allocation, integration progress, and returns relative to the goodwill and intangible assets recorded.
- Consider the potential conversion, dilution, settlement choices, and market-value exposure associated with the 2025 convertible notes.
- Separate recurring tax performance from the reported discrete tax benefits, and track developments in the disclosed legal proceedings and purchase commitments.